Skip to content

eSource makes the eCRF reliable, accurate and timely

eSource makes the eCRF reliable

Bridging the gap

eSource is the bridge between the protocol and the eCRF fields. To understand why, we need to understand what each does.

The protocol describes the purpose of the study, the core hypotheses, the endpoints that are to be collected, and the resulting procedures to be performed to support those endpoints. The eCRF then translates a subset of those endpoints (i.e., the ones collected by the research site) into target data fields to be completed by site personnel.

While the eCRF is a distillation of the key fields required for analysis, it does not cover all the specifications of the protocol. This is because the protocol specifies not only the target endpoints, but also the workflows that support those endpoints.

For instance, the protocol may specify that vitals are to be taken when the patient has been in sitting position for 5 minutes, and that the same arm is to be used throughout. These specifications ensure that blood pressure readings are done in a consistent manner, so that measurements can be compared across time, with less risk of confounding factors.

However, the eCRF usually includes only the diastolic and systolic measurements, and excludes those other data points regarding how the vitals were taken. Instead, those data fields are usually captured by research sites on their source forms, with subsequent review by the CRA to ensure compliance.

eSource – Critical to following the protocol

This is where eSource comes in. eSource translates the protocol into an actionable, logically sequenced series of visits and procedures that serve as a workflow tool for the research team. For instance, well written eSource will contain detailed and pop-up instructions to clarify requirements; branching logic to guide the team down the appropriate workflow path; and alerts and edit checks not only to flag inappropriate values but also action items, such as the need to re-educate patients or to document deviations.

eSource, therefore, is critical to ensure that sites are following the protocol, capturing not just the data necessary to populate the eCRF’s, but also ensuring that the data is captured in the manner the protocol requires. From a data management perspective, eSource makes the eCRF data reliable, in that the data is meaningful and comparable across sites and subjects. This is different, and in addition to, the data being accurate and contemporaneous.

Introducing the CRIO Model – CRIO eSource/EDC 

With either CRIO’s eSource/EDC all-in-one solution or with our eSource to EDC integration (where CRIO’s eSource automatically populates the eCRF fields directly into the EDC), we give data managers immediate access to the data, with no need for data transcription by the sites into EDC or for manual source data verification.

Thus, eSource is a very powerful lever for sponsors. It enforces protocol compliance and makes the data in EDC Attributable, Legible, Contemporaneous, Original, and Accurate (ALCOA) – the gold standard for clinical data.

Discover CRIO eSource/EDC.

by Raymond Nomizu CEO at CRIO
Share this post
You may also find interesting
Explore our Blog
Progress notes are vital to source data Running a Study

Progress Notes are Vital to Source Data

Progress notes are free-text entries by the investigator, coordinator or study team member that are inserted into the source record. Generally, these play a critical and highly undervalued role in the study process. Progress notes are often used to: Clarify or confirm any data points that may appear as outliers, even before a query is...

Hand of businessman using smart phone with coin icon, technology, clinical trials operations Running a Study

Sponsors, Funding is Tight – Be Smart with Your Money

Getting a new product to market is expensive. There are a variety of studies and research that point to a wide array of costs, but generally speaking, it costs nearly $3 billion dollars to bring a new drug to market. Yes, you read that correctly. Beyond this, the success rate of a new compound to...

DCT Draft Guidance explained Running a Study

The FDA’s Decentralized Clinical Trials Draft Guidance Explained

The highly anticipated Decentralized Clinical Trials (DCT) draft guidance from the FDA was finally released on 02-May-2023. In this 19-page document, the FDA outlines its current thinking around the concept of DCTs. From the outset of the draft guidance, the FDA makes a clear point on what DCTs can mean for patients and the patient...